I think maybe the money's what's throwing you off here today.
Followers | 199 |
Posts | 17,212 |
Boards Moderated | 2 |
Alias Born | 02/17/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KMAG LVL2: If anybody wants a few of my shares, there's a 100k block at .0035 for sale. There's more if you want em, for .01
There, our very own LVL2. Lol
Party on
Now, at 12.... Party on.
** Pulls tie loose ** "Whew, gettin warm in here. Ready?" Lol
Huh, is that where I got those 8s from? Lol. Thanks, shorty.
DUTV.....? Check it out. Sleeper that went over 100% today on air.
Thanks to the whacka whacka whacka for the 8s. Put me at 3,000,000 shares. Party on.
Well put. Agreed.
Love these lotto plays. Patience pays off if you can afford it.
He did. I spoke with him. He is currently now a contractor and Lance is CEO. It was actually a pretty good phone conversation. Shirley was straight-forward and not a salesman. Believe me or not, but I'm just a regular guy like the rest of us (most) on here. I'm watching closely for updates via filings.
Personal sentiment: Buy/Hold and Party on
Yes, there is some leeway. If you have less than 25k it can get messy quick though, without margin.
A lot of new traders hop in thinking they can get out right away... Until a little message appears when they submit a sell order that same day. That wonderful message that basically says, "You're broke, stop trading. You need $25k to day trade." Lol.
Very true. All one needs to do is browse otcmarkets.com. There are many Nasdaq etc. worthy companies on there. The requirements are more simple and affordable, however, some credibility is lost because of the abundance of P&Ds in OTCville.
Party on
Re-entered at 544 with some 650s. Still calling 600 easy by January.
If you're new to the party, thanks for joining. If you've been here awhile, congrats.
Party on.
Someone backed up those 69s before I could get to em! Then a 100k on the bid support. Nice little action (yes, even though red).
New to trading? Please don't fall into the hype.
Playing SVEN is nothing but supporting any (crooks) involved inside. The insiders are the only ones who are guaranteed to win, unless anybody here has a SVEN printing press in their basement, then go for it.
Someone posted a photo of the two major guys inside SVEN, there are better things to do than freely put money in their crooked pockets, and tell other people to also do the same.
IMO blah blah blah
I'm not looking for cheap shares. Simply trying to help others skip mistakes I've made in the past :)
If you want though, feel free, party with SVEN... But you might wake up with a crazy hangover.
Bwahaha! Nice.
Lol. Yup.
The P/E is an equation though. Not just a filed number. ie. Market Value per Share divided by Earnings per Share (EPS)
Which shows extreme over-evaluation.
Party on
I think SVENs first mistake was: Not dumping the price before this pump. Even out the stats before you tout yourself, then issue yourself some shares.... I'm actually quite surprised they didn't start this below .10
I'm rarely serious around here. Lol.
Actually a real fact (not joking at all): SVEN P/E is 333. AAPL is 13.2. Source: Etrade.
It's kind of a joke..... Just like SVEN.
IMO blah blah blah
Lol. Party on, Wayne
It probably came from Aruba... Lol.
Me neither. Still here.
Fact: You can also lose your rear-end playing SVEN. Don't go home and kick the dog, he didn't send you that email.
Fact: SVEN has a p/e that's 100 times that of AAPL...
Fact: APS is the biggest U.S penny pumper, and you can make tons of dough with this.
Does playing this make you any better or worse than the folks running the show? Hmmmm.
Waiting for the " " to come off "acquisitions"... Time will tell.
Play the pumps, but don't forget they're pumps. Keep in mind the p/e for SVEN is 329. The computer conglomerate AAPL has p/e of "only" 13........
You mean "acquisitions"? Lol
I'm not gone. I was in the mood for a lotto... I don't think Charles and Charles are done with this. They might be rooster suckers, but I think this ticker could be a money maker. If I lose the couple grand... So be it, it's YE... If they pump these recent "acquisitions", then I get some dirty money (which, yes, I don't like. But this is the penny game, and anybody around here knows that's how the majority of these stinks are) If you want honesty, put the cash under the mattress.
Jee Golly.... This is a $50 million company? That means it's really real, for real, right?
Still here. Holding..... Impatiently. Lol
That wasn't all dilution... I know for a fact... And sorry about that, I was sick of this company. Could care less if it breaks out, got some new shoes anyway.
"Awesomestocks" email, 11/26/12:
On December 12th, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd. ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products.
Most recently IMUN began to make key scientific breakthroughs in it's battle against cancer by filing key patents & protecting their intellectual property.
IMUN's Patent For Allogeneic Cell Therapy
On October 11th, IMUN announced that Immunovative Therapies, Ltd. ("ITL") has been granted a U.S. Patent entitled "METHOD FOR ALLOGENEIC CELL THERAPY," which was issued September 25, 2012, under Patent No. 8,273,377. Foreign versions of this patent are pending around the world. This patent covers the proprietary method that utilizes immune cells from a normal donor to elicit an anti-tumor mechanism that mimics the Graft vs. Tumor (GVT) effect of non-myeloablative allogeneic stem cell transplants ("Mini-Transplant") without the toxicity of Graft vs. Host Disease (GVHD).
IMUN Patents T-Cell Compositions That Elicit A Type I Cytokine Response
On October 16th, IMUN announced that Immunovative Therapies, Ltd. ("ITL") has received a Notice of Allowance for product Claims 17-28 contained in US Patent Application 12/909,517 entitled: "T-CELL COMPOSITIONS THAT ELICIT A TYPE I CYTOKINE RESPONSE." The additional claims contained in the application covering methods and uses are still pending. Foreign versions of the patent application are also pending.
On October 11, 2012, IMUN announced the issuance of US Patent No. 8,273,377 entitled "METHOD FOR ALLOGENEIC CELL THERAPY," which covered the scientific breakthrough discovery of the "Mirror Effect™." The Mirror Effect™ stimulates the same powerful anti-tumor immune response proven capable of killing chemotherapy-resistant solid tumors and blood cancers, but without the Graft vs. Host Disease (GVHD) toxicity or the need for a matched tissue donor.
IMUN Expands Collaboration With U. of Arizona to Expand Leukemia & Cancer Clinical Trials
On November 13th, IMUN announced that Immunovative Therapies, Ltd. ("ITL") and The University of Arizona Cancer Center (UACC) and The University of Arizona Medical Center (UAMC) (University Campus and Diamond Children's) have agreed to expand their current collaboration to include investigator-initiated clinical trials using AlloStim™ and AlloVax™, with an initial focus on adult and pediatric leukemias and childhood cancers that are refractory to standard treatments.
IMUN Upgrades State-of-the-Art Manufacturing Facility
This morning IMUN once again made headlines reporting that the company has successfully completed upgrades to its state-of-the-art Jerusalem (Israel) GMP cell manufacturing facility and it's GMP operations in order to comply with the anticipated increased demand and higher level of GMP compliance requirements of advanced clinical trials. The timely completion and validation of this GMP manufacturing facility enables the Company, from a logistics standpoint, to launch a Pivotal Phase II/III trial as planned during early 2013.
IMUN Granted U.S. Patent For Method of Simulating a Therapeutic Immune Effect In a Patient
IMUN once again made headlines this morning by reporting the company secured the grant of United States Letters Patent ("U.S. Patent") entitled "METHOD FOR STIMULATING A THERAPEUTIC IMMUNE EFFECT IN A PATIENT," which was issued October 20, 2012, under Patent No. 8,298,587. Foreign versions of this patent are still pending around the world.
This is the 12th U.S. patent issued to ITL covering its lead biological drug candidate called AlloStim™ with additional patents still pending. The next product in the pipeline, AlloVax™, is an individualized anti-cancer vaccine which combines AlloStim™ with chaperone proteins called "CRCL." CRCL technology, in-licensed from the University of Arizona and is covered by US Patent No. 6,875,849 entitled "Methods of recovering chaperone proteins and complexes thereof."
This brings IMUN's currently issued patent portfolio to 13 issued US patents with additional patents pending worldwide.
Biotechs Set For A Huge 2013
In 2012 Biotechnology companies saw tremendous gains with...
*Arena Pharmaceuticals (ARNA) gaining 794% in the first 6 months of the year!
*OncoSec Medical (ONCS) soared from just $0.14 to $0.49 for 250% gains...
*Peregrine Pharma (PPHM) rose from just $0.39 to $5.50 in just 3 months for gains of 1,310%!
Most impressively PCYC which once traded for just $0.79 reached a high of over $70.00 for gains of over 8,860%!
Over the years the biotech sector has built an unusual cult like following with millions of investors as this sector provided some of the largest gains for investors & it's no secret that this sector is once again setting itself up to deliver huge gains in 2013.
Could IMUN be the company to lead the next wave of the biotech stock rally?
With the continued positive strides the company is taking & with Phase 2 & 3 trials set to begin in early 2013, we believe IMUN could prove itself to be a bargain at a current price per share of just $0.25.
Make sure to further your research on IMUN tonight & be ready for the opening bell tomorrow morning!
Happy Trading,
AwesomeStocks.com
Follow Us On Twitter @AwesomeStocks (over 1,000,000 follow!)
DISCLAIMER
Please Read Carefully:
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. AwesomeStocks.com is a web property owned by Tribeca Investments Ltd. Tribeca Investments., Ltd. had been compensated up to $25,000 USD via bank wire for the advertising of IMUN - Immunovative Inc. by Winning Media. Previously, Tribeca Investments., Ltd. had been compensated up to $50,000 USD via bank wire for the advertising of IMUN - Immunovative Inc. by Winning Media. Anyone viewing this newsletter should assume the hiring party or affiliates of the hiring party own shares of IMUN of which they plan to liquidate, further understanding that the liquidation of those shares may or may not negatively impact the share price. Tribeca Investments Ltd affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Tribeca Investments Ltd. owns no shares of IMUN. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of your investment.
FOR COMPLETE COMPENSATION DISCLOSURE AND RISKS INVOLVED PLEASE VIEW OUR FULL DISCLAIMER AT: http://tribecainvestmentsltd.com/disclaimer
This message sent to mashcashprofits@gmail.com by contact@awesomestocks.com
Tribeca Investments Ltd
Corner Hutson & Eyre Street Blake Building
Suite 302
Belize City, Belize 78583
You opted in to this list from: www.AwesomeStocks.com (More info)
Unsubscribe | Update Profile/Email Address | Forward to a Friend
The key is to keep some actual assets/revs around. We will see. I haven't lost all patience, however, it's difficult to piss me off. Lol.
I rarely expect a stink to have current (filed) numbers on otcmarkets, but ICPA has so much publicity that it seems every little thing will help show "honesty".
Holding ICPA.
Lol. Party on
Rich, that is probably your best post ever, great question. Sincerely. You know me, you know I'm serious, not being a smart a**, even though I'm long.
Steve, as a "shareholder", I also have to ask the same question that Rich did. I've wondered about updating the number one source of company information. It seems like every quarter, or god forbid when the info changes, is a reasonable request. I feel swindled and I don't like it right now. Prove us wrong, please. Again, I didn't break the first rule, so I could give a sh** if this tanks, but I'd probably rather make some money... So, if you have time after taking care of the important things as a CEO, it would be nice if you could answer why it's taking so long for an OTC update. Thank you in advance.
Oh man, you've been so back and forth on this one. C'mon now...
.01s gone